Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies

Roberta Palla; Carla Valsecchi; Mariateresa Bajetta; Marta Spreafico; Raimondo De Cristofaro; Flora Peyvandi

doi:10.1160/TH10-06-0417

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(02): 381-385
DOI: 10.1160/TH10-06-0417

Letters to the Editor

Schattauer GmbH

Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies

Authors

Roberta Palla

¹A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy
Carla Valsecchi

¹A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy
Mariateresa Bajetta

¹A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy
Marta Spreafico

¹A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy
Raimondo De Cristofaro

²Hemostasis Research Centre, Institute of Internal Medicine and Geriatrics, Catholic University School of Medicine, Rome, Italy
Flora Peyvandi

¹A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy

Abstract

Volltext

Referenzen

References
1 Peyvandi F, Palla R, Lotta LA. et al. ADAMTS-13 as-says in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631-40.
2 Studt JD, Hovinga JA, Antoine G. et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544.
3 Zhou Z, Han H, Cruz MA. et al. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease. Thromb Haemost 2009; 101: 1070-1077.
4 Meyer SC, Sulzer I, Lämmle B. et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-867.
5 Eckmann CM, De Laaf RT, Van Keulen JM. et al. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1331.
6 Raife TJ, Cao W, Atkinson BS. et al. Leukocyte pro-teases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-1674.
7 Feys HB, Vandeputte N, Palla R. et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 2053-2062.
8 Studt JD, Böhm M, Budde U. et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-1887.
9 Tripodi A, Chantarangkul V, Böhm M. et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-1609.
10 Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006; 4: 1146-1148.
11 Tripodi A, Peyvandi F, Chantarangkul V. et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-1541.
12 Peyvandi F, Lavoretano S, Palla R. et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-239.
13 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
14 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
15 Mannucci PM, Peyvandi F. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). In: Postgraduate Haematology. Blackwell Publishing Ltd; 2005. pp. 876-884.
16 Kato S, Matsumoto M, Matsuyama T. et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
17 Shelat SG, Smith P, Ai J. et al. Inhibitory autoanti-bodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4: 1707-1717.
18 Starke R, Machin S, Scully M. et al. The clinical utility of ADAMTS13 activity, antigen and autoanti-body assays in thrombotic thrombocytopenic purpura. Br J Haematol 2006; 136: 649-655.
19 Kremer Hovinga JA, Vesely SK, Terrell DR. et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
20 Feige MJ, Simpson ER, Herold EM. et al. Dissecting the alternatively folded state of the antibody Fab fragment. J Mol Biol 2010; 399: 719-730.

Zusatzmaterial

Zusatzmaterial (PDF)